Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)
Status:
Withdrawn
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
It is our primary hypothesis that pretreatment with arformoterol will provide superior
protection against EIB in children with mild-moderate asthma compared to placebo added to the
current asthma regimen.
Our secondary hypothesis is that nebulized arformoterol has comparable protection against EIB
compared to inhaled formoterol by dry powder inhaler.